PCM
INDV icon

Prelude Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Prelude Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,758
Closed -$255K – 1164
2025
Q1 		$255K Sell
26,758
-215,788
-89% -$2.27M 0.02% 787
2024
Q4 		$3.01M Buy
+242,546
New +$2.5M 0.19% 111

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's INDV Position: Q2 2025 in Review

Prelude Capital Management sold out of Indivior Pharmaceuticals (INDV) in Q2 2025, closing a stake of 26,758 shares — an estimated $255K sold.

Prelude Capital Management first reported a position in INDV in Q4 2024 and held it in 2 quarters. The position peaked at $3.01M in Q4 2024. 120 funds tracked by Wall St. Rank hold INDV as of Q2 2025.

  • Prelude Capital Management reported no remaining Indivior Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 26,758 Indivior Pharmaceuticals shares in Q2 2025, an estimated $255K.
  • Prelude Capital Management first reported a position in Indivior Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Prelude Capital Management's Indivior Pharmaceuticals position peaked at $3.01M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.